Semaglutide vs tirzepatide side effects: what the head-to-head trials found

Reviewed 12 sourcesPublished by PepVault

Semaglutide vs tirzepatide side effects in the same trials: nausea, vomiting, reflux, hair loss and injection-site rates side by side, and how many stopped.

A woman in a cobalt top peeling an orange on a stone wall among lemon trees
Last reviewed
Sources
12
Questions
8
Compounds
2

The short answer

In SURMOUNT-5, the one trial that gave both at their weight-loss doses (751 adults, 72 weeks), the side effects were nearly the same: nausea in 44% on each, diarrhoea in 23%, constipation in about 28%. Semaglutide brought more vomiting (21% against 15%) and reflux; tirzepatide more injection-site reactions (9% against under 1%). Fewer stopped tirzepatide over side effects: 6.1% against 8.0%.

Every number checked at its primary source · · 12 sources · How we research

Evidence: Two open-label randomised head-to-head trials in people (SURMOUNT-5 and SURPASS-2) and each drug's main placebo-controlled phase 3 trial, with adverse-event counts read from their ClinicalTrials.gov results; the FDA labels; the sponsor's report of SURMOUNT-5's discontinuations; one animal study on GIP and nausea.

A woman in a cobalt top peeling an orange on a stone wall among lemon trees

Which has fewer side effects, semaglutide or tirzepatide?

Neither, by much, when the two are compared in the same trial. SURMOUNT-5 randomised 751 adults with obesity and no diabetes to tirzepatide (Zepbound) or semaglutide (Wegovy) for 72 weeks. Each group climbed in four-week steps to the highest dose a person tolerated: 10 or 15 mg of tirzepatide, 1.7 or 2.4 mg of semaglutide12. Two thirds were women and the average age was 452. It was the first trial to compare the two in people with obesity and no diabetes, and most side effects were mild to moderate and came during the dose climb1.

The share of people in each group who reported each effect at any point in the 72 weeks, from the trial's results record2:

Side effectTirzepatide (10 or 15 mg)Semaglutide (1.7 or 2.4 mg)
Nausea43.6%44.4%
Constipation27.0%28.5%
Diarrhoea23.5%23.4%
Vomiting15.0%21.3%
Fatigue10.4%12.2%
Reflux (heartburn)6.1%10.6%
Burping9.9%7.7%
Injection-site reaction8.6%0.3%
Hair loss8.3%6.1%
Headache7.2%7.2%
Dizziness6.4%4.8%
Any serious adverse event4.8%3.5%

The record lists each effect that reached 5% in either group, under the term it was reported as; injection-site redness or itching reported under their own terms is not in the injection-site row2.

Read across the rows and the stomach is close to a tie, with two exceptions: vomiting and reflux were less common on tirzepatide. Tirzepatide's extras sit outside the stomach, at the injection site and in the hair. One caution comes with the design: the trial was open-label, so everyone knew which drug they were taking, and that can colour what people report1.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault logs each side effect with its strength, from minimal to very severe, against the compound and the date, so you can read back the weeks after each step-up.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Did more people stop semaglutide because of side effects?

A few more did. Lilly, the trial's sponsor, reported that 6.1% of people on tirzepatide and 8.0% on semaglutide stopped treatment because of an adverse event, and noted that the trial was not designed to compare the two drugs' safety12. Both are small shares: more than nine in ten people on either drug did not stop over side effects.

Serious adverse events went slightly the other way, 4.8% on tirzepatide against 3.5% on semaglutide, and no deaths were recorded in either group2. A serious adverse event is any event that put someone in hospital or was otherwise grave, whether or not the drug caused it (an adverse reaction is one the drug is judged to cause).

Why do two different drugs cause the same side effects?

Because they share the receptor behind most of them. Semaglutide switches on one hormone receptor, GLP-1; tirzepatide switches on GLP-1 and a second one, GIP, another gut hormone that helps release insulin after a meal910. GLP-1 turns appetite down in the brain and slows how fast the stomach empties, so food sits longer, and both drugs' labels state that they delay stomach emptying910. That slower stomach is where much of the nausea, fullness and reflux comes from.

The GIP half was expected to soften it. In mice, rats and musk shrews, switching on GIP receptors blocked the vomiting and eased the sick behaviour that a GLP-1 drug causes, while food intake and weight still fell11. That is an animal result. In people at full doses, SURMOUNT-5 found less vomiting on tirzepatide but the same nausea2: the animal finding held for vomiting, not for nausea.

Does the comparison change at the diabetes doses?

SURPASS-2 is the other head-to-head trial. It gave 1,879 adults with type 2 diabetes, all on metformin, tirzepatide at 5, 10 or 15 mg or semaglutide at 1 mg, the Ozempic dose used at the time, for 40 weeks; like SURMOUNT-5 it was open-label3. Semaglutide here sat below the doses used for weight loss, and the rates follow that4:

Side effectTirzepatide 5 mgTirzepatide 10 mgTirzepatide 15 mgSemaglutide 1 mg
Nausea17.4%19.2%22.1%17.9%
Diarrhoea13.2%16.4%13.8%11.5%
Vomiting5.7%8.3%9.8%8.3%
Less appetite7.4%7.2%8.9%5.3%
Any serious adverse event7.0%5.3%5.7%2.8%

Tirzepatide 5 mg and semaglutide 1 mg gave the same nausea, and tirzepatide's rose a few points by 15 mg. Low blood sugar under 54 mg/dL was uncommon on both: 0.2 to 1.7% across the tirzepatide doses and 0.4% on semaglutide3. Serious adverse events were 5 to 7% on tirzepatide against 3% on semaglutide3, a wider gap than SURMOUNT-5's 4.8% against 3.5%.

Why not compare the Wegovy and Zepbound trials' own numbers?

Because separate trials count differently, and their placebo groups show it. STEP 1 (Wegovy 2.4 mg, 68 weeks) and SURMOUNT-1 (Zepbound 5, 10 and 15 mg, 72 weeks) are the two drugs' main weight trials, each against a placebo, a dummy shot with no drug in it57. Their results records give68:

Side effectSTEP 1 placeboSemaglutide 2.4 mgSURMOUNT-1 placeboTirzepatide 5 mgTirzepatide 10 mgTirzepatide 15 mg
Nausea17.4%44.1%9.8%25.4%34.1%31.9%
Diarrhoea15.9%31.5%7.9%20.3%22.5%23.7%
Vomiting6.6%24.6%1.9%9.2%11.6%12.9%
Constipation9.5%23.4%5.9%17.9%18.4%12.7%

With no drug at all, 17.4% reported nausea in STEP 1 and 9.8% in SURMOUNT-1. Something other than the drug moved those numbers: the people, the sites and the way reports were collected differ from trial to trial, and set side by side they make semaglutide look worse than the head-to-head trials found. The time windows differ too: STEP 1's record runs from week 0 to 75, and SURMOUNT-1's to week 193, because about a third of its participants, those with prediabetes, stayed on for three years68.

So the same-trial tables above are the fair comparison. Each drug's own rates, dose by dose, are in Ozempic and Wegovy side effects and Mounjaro and Zepbound side effects; its climb, step by step, is in Semaglutide week by week and Tirzepatide week by week, and the doses behind each step are in Wegovy and Ozempic dosage and Tirzepatide dosage.

Which side effects really differ between them?

Injection-site reactions. A skin reaction where the shot went in, such as redness or itching, was reported by 8.6% on tirzepatide and 0.3% on semaglutide in SURMOUNT-52. The Zepbound label counts 6 to 8% across its doses against 2% on placebo, and far more often in people whose immune system made antibodies to tirzepatide (11.3% against 1%)9. The Wegovy label counts 1.4% against 1%10.

Hair loss. 8.3% against 6.1% in SURMOUNT-52. The Zepbound label ties it to the weight loss itself, and both labels find it mostly in women: on Zepbound 7.1% of women and 0.5% of men, on Wegovy 2.4 mg 4% of women and 0.9% of men, rising to 5.8% overall at Wegovy's 7.2 mg910. With two thirds of SURMOUNT-5 women, its rates sit near the women's figures.

Vomiting and reflux. Both were less common on tirzepatide: vomiting 15.0% against 21.3%, reflux 6.1% against 10.6%2. Burping went slightly the other way, 9.9% against 7.7%.

Birth-control pills. Only tirzepatide's label sets a rule here: it can make the pill less reliable, so the Zepbound label advises a non-oral method, or adding a barrier method, for four weeks after starting and after each step-up9. The Wegovy label carries no such instruction10.

Commonly reported: people who move from semaglutide to tirzepatide often describe a quieter stomach and less heartburn, while others notice no change at all; an itchy or red patch at the injection site comes up more on tirzepatide, usually gone within a day or two.

Are the serious risks different?

On the labels, no. Both carry the same boxed warning, the FDA's most prominent kind, about thyroid C-cell tumours seen in rodents; whether that happens in people is unknown910. Both list pancreatitis, gallbladder disease, low blood sugar when taken with insulin or a sulfonylurea, and kidney injury from fluid lost to vomiting or diarrhoea910. In SURMOUNT-5, serious gallstone events were rare on both: 2 people on tirzepatide and 3 on semaglutide2.

When to get help On either drug, severe stomach pain that does not go away, sometimes spreading to the back, with or without vomiting, is the reason to stop the dose and contact your prescriber straight away910.

How do you tell what your own shot is doing?

Write it down the same way every week. The trials' numbers are group averages, and your weeks are your own; a plain record lets you and your prescriber compare like with like when you weigh a step-up or a switch between the two, which stays the prescriber's decision.

  1. Log each side effect on the day it happens, with how strong it was, so a rough first week does not blur into a fine third.
  2. Note the dose you were on that week: most nausea, vomiting and diarrhoea gather in the weeks after each step-up and ease with time9.
  3. Note where each injection went, so a reaction that keeps coming back at one spot is easy to see.
  4. Compare the same weeks after each step, not your worst day against your best.
  5. Bring the record to your prescriber when a dose change or a switch is on the table.

PepVault logs each side effect with its strength, from minimal to very severe, against the compound and the date, so you can read back the weeks after each step-up. Log it in PepVault

PepVault records the injection site with every dose, pens included, so a reaction that returns at one spot shows up in your history. Log it in PepVault

Track it in the app

Sources

  1. Aronne LJ et al.; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393:26-36. PubMed 40353578
  2. ClinicalTrials.gov NCT05822830 (SURMOUNT-5; sponsor Eli Lilly and Company). Results: adverse events, baseline characteristics, arms. clinicaltrials.gov
  3. Frías JP et al.; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503-515. PubMed 34170647
  4. ClinicalTrials.gov NCT03987919 (SURPASS-2; sponsor Eli Lilly and Company). Results: adverse events. clinicaltrials.gov
  5. Wilding JPH et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002. PubMed 33567185
  6. ClinicalTrials.gov NCT03548935 (STEP 1; sponsor Novo Nordisk A/S). Results: adverse events, week 0 to 75. clinicaltrials.gov
  7. Jastreboff AM et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216. PubMed 35658024
  8. ClinicalTrials.gov NCT04184622 (SURMOUNT-1; sponsor Eli Lilly and Company). Results: adverse events, baseline to week 193. clinicaltrials.gov
  9. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed, SPL version 40, September 2, 2026. dailymed.nlm.nih.gov
  10. Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information. DailyMed, SPL version 19, June 30, 2026. dailymed.nlm.nih.gov
  11. Borner T et al. GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Diabetes. 2021;70:2545-2553. PubMed 34380697
  12. Eli Lilly and Company. Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in the New England Journal of Medicine. Press release (PR Newswire), May 11, 2025. investor.lilly.com

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo